Search results
Results from the WOW.Com Content Network
Rituximab, sold under the brand name Rituxan among others, is a monoclonal antibody medication used to treat certain autoimmune diseases and types of cancer. [18] It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia (in children and adults, but not recommended in elderly patients), rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura ...
cancer Amivantamab: Rybrevant: BsAb: human: Epidermal growth factor receptor (EGFR), cMet: Y: non-small cell lung cancer: Anatumomab mafenatox [17] Fab: mouse: Tumor-associated glycoprotein 72 (TAG-72) non-small cell lung cancer: Andecaliximab [18] mab: chimeric: gelatinase B: gastric cancer or gastroesophageal junction adenocarcinoma Anetumab ...
Osimertinib, sold under the brand name Tagrisso, [6] is a medication used to treat non-small-cell lung carcinomas with specific mutations. [7] [8] It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor.
A drug that disappointed in 2018 will get an unexpected dance at the big ball. Skip to main content. Sign in. Mail. 24/7 Help. For premium support please call: 800-290-4726 more ways ...
An oral pill in clinical trials shows promising results in lung cancer patients with advanced disease. Lung cancer is the third most common cancer in the U.S., according to the Centers for Disease ...
Acalabrutinib, sold under the brand name Calquence, is a anti-cancer medication used to treat various types of non-Hodgkin lymphoma, including mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma. [7]
Zanubrutinib, sold under the brand name Brukinsa, is an anticancer medication used for the treatment of mantle cell lymphoma (MCL), Waldenström's macroglobulinemia (WM), marginal zone lymphoma (MZL), and chronic lymphocytic leukemia (CLL).
Bexarotene, sold under the brand Targretin, is an antineoplastic (anti-cancer) agent used for the treatment of cutaneous T cell lymphoma (CTCL). [4] It is a third-generation retinoid. [5] It was approved by the U.S. Food and Drug Administration (FDA) in December 1999, and the European Medicines Agency (EMA) in March 2001.